Oral versus intravenous iron supplementation in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 21, Issue SUPPL. 3, 2001, Pages

  Johnson, David W ^a   Herzig, Karen A ^a   Gissane, Ruth ^a   Campbell, Scott B ^a   Hawley, Carmel M ^a   Isbel, Nicole M ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Erythropoietin; Ferritin; Hemoglobin; Iron economics; Prospective studies

Indexed keywords

ERYTHROPOIETIN; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; IRON DERIVATIVE; IRON DEXTRAN; IRON POLYMALTOSE; IRON SORBITEX;

ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EPIDEMIOLOGY; GASTROINTESTINAL TOXICITY; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; INFECTION; INJECTION SITE; IRON STORAGE; IRON THERAPY; PATIENT MONITORING; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT;

EID: 0035570737     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080102103s41     Document Type: Article

References (37)

1. Erythropoietin in chronic renal failure
2. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients
3. Health-related quality of life associated with recombinant human erythropoietin therapy for pre-dialysis chronic renal disease patients
4. Strategies for iron supplementation: Oral versus intravenous
5. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients
6. Intravenous ferric saccharate as an iron supplement in dialysis patients
7. Management of iron substitution during r-HuEPO therapy in chronic renal failure patients
8. Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in erythropoietin-treated patients
9. Evidence-based recommendations for the clinical use of recombinant human erythropoietin
10. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure
11. Biochemical and haematological targets
12. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure
13. A prospective cross-over trial comparing intermittent intravenous and continuous oral iron supplementation in peritoneal dialysis patients
14. Intravenous iron for CAPD populations: Proactive or reactive strategies?
15. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: A single center comparative study
16. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: A prospective, cross-over trial
17. Iron status and iron supplementation in peritoneal dialysis patients
18. Failure of CAPD patients to respond to an oral iron absorption test
19. Iron absorption after single pharmacological oral iron loading test in patients on chronic peritoneal dialysis and in healthy volunteers
20. Reduced nPCR in patients with gastrointestinal side effects due to ferrous sulfate
21. "Oversaturation" of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients
22. Characterisation of iron availability from 3 different iron preparations in dialysis patients
23. Intravenous iron hydroxy saccharate: Establishing the optimum dose
24. The safety of intravenous iron dextran in hemodialysis patients
25. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans
26. Iron and the sex difference in heart disease risk
27. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000
28. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency
29. Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey
30. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit
31. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients
32. Adverse effects of intramuscular iron injection
33. Sarcoma after injection of intramuscular iron
34. Iron dextran treatment in peritoneal dialysis patients on erythropoietin
35. Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients
36. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin
37. Chronic administration of iron dextran into the peritoneal cavity of rats